Skip to content
Parakho

IOL Chemicals & Pharmaceuticals Ltd

NSE IOLCPBSE 524164iolcp.com

Q1 FY27, unaudited

Revenue
₹756.26 Cr
Profit after tax
₹64.48 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations756.26+37.08%2,319.06
Other income8.18+10.99%21.28
Total income764.44+36.74%2,340.34
Employee benefit expense71.21+23.52%248.26
Finance costs3.64−13.95%14.55
Depreciation & amortisation21.32+7.95%80.17
Total expenses677.67+31.97%2,144.69
Profit before tax86.77+90.54%184.44
Tax expense22.29+92.49%46.72
Profit after tax64.48+89.87%137.72
Total comprehensive income63.45+90.43%140.32
Earnings per share
Earnings per share, basic₹2.20₹4.69
Earnings per share, diluted₹2.20₹4.69

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

IOL Chemicals and Pharmaceuticals reported Q1 FY27 revenue of Rs 756 crore, up 37% year-on-year, with EBITDA of Rs 111 crore and PAT of Rs 64.5 crore. Management attributed the growth to higher capacity utilization, an improved product mix, and continued diversification of the API portfolio beyond ibuprofen, with non-ibuprofen products now contributing 43% of pharmaceutical revenue versus 36% a year earlier. Exports rose to 28.5% of revenue from 24.4%, and management reiterated FY27 guidance of 15-20% revenue growth with an EBITDA margin of 14-15%.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 57 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.